N

Nephrology Associates of Northern Virginia | Fairfax, VA

Research site

(Unclaimed)

Location

13135 Lee Jackson Memorial Highway Suite #135, Fairfax, Virginia, United States of America

Site insights

Top conditions

Top treatments

Ferric Citrate

Lixivaptan

Bardoxolone Methyl

Sitagliptin

Atrasentan

Finerenone

Vildagliptin

Tolvaptan

PF-00489791

RO7434656

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 15 total trials

A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy

The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial....

Enrolling

Primary Membranous Nephropathy

Drug: SNP-ACTH (1-39) Gel

Drug: Rituximab

A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis

The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-a...

Enrolling

Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Drug: Avacopan

Drug: Standard of Care

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression (IMAGINATION)

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of sefaxersen (RO7434656), a novel Antisense Oligonucleotide (ASO...

Enrolling

Primary IgA Nephropathy

Drug: Placebo

Drug: Sefaxersen (RO7434656)

Atrasentan in Patients With IgA Nephropathy (ALIGN)

The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA...

Active, not recruiting

Immunoglobulin A Nephropathy

IgA Nephropathy

Drug: Placebo

Drug: Atrasentan

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

This is a 2-part (phase 2b/3) prospective, interventional, multicenter, randomized, double-blind, placebo-controlled study. Part 1 (phase 2b) is a do...

Enrolling

Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease in Patients With ESKD

Drug: Placebo

Drug: CSL300